# Spironolactone

Drug · id `cardio:spironolactone` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Aldactone

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: High blood pressure; Heart failure  

## In plain language

Spironolactone, sold as Aldactone, is an aldosterone antagonist, a medicine taken by mouth that blocks the hormone aldosterone. The US label read, for Aldactone tablets, lists four uses: heart failure with reduced ejection fraction in people with the more severe symptom classes (NYHA class III to IV), to increase survival, manage swelling and reduce hospital stays for heart failure; add-on treatment of high blood pressure; swelling in adults with cirrhosis of the liver or in the nephrotic syndrome when the measures the label names first have not worked well enough; and primary hyperaldosteronism.

## Technical summary

RxNorm ingredient 9997; UNII 27O7W4T232. MeSH descriptor D013148 is Spironolactone. Class: Aldosterone Antagonist (FDA established pharmacologic class, RxClass). The label read is the Pfizer Laboratories Div Pfizer Inc label for Aldactone tablets, application NDA012151, effective 2025-11-28 in openFDA. The plan row pointed at a spironolactone and hydrochlorothiazide combination label; the single-ingredient brand label replaces it. The combination product (Aldactazide, NDA012616) and generic labels were not read. This page records label indications, the mechanism sentence and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Patients with NYHA class III to IV heart failure (reduced ejection fraction), hypertension, edema or primary hyperaldosteronism, as described in the US label of Aldactone tablets

Recipient: Recipient not specified; Population: Patients described in the indications section of the label: people with NYHA class III to IV heart failure and reduced ejection fraction, people with hypertension, adults with edema from cirrhosis of the liver or the nephrotic syndrome, and people with primary hyperaldosteronism. The passages read do not state an age range for each use.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated for each use in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Aldactone (spironolactone tablets, Pfizer Laboratories Div Pfizer Inc, application NDA012151; the version dated 2025-11-28 in openFDA) describes spironolactone as an aldosterone antagonist. It lists the treatment of NYHA class III to IV heart failure with reduced ejection fraction to increase survival, manage edema and reduce the need for hospitalization for heart failure; add-on treatment of hypertension; the management of edema in cirrhosis of the liver and in the nephrotic syndrome in the settings the label names; and treatment of primary hyperaldosteronism, as short-term preoperative treatment and as long-term maintenance therapy in the settings the label names.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label: people with NYHA class III to IV heart failure and reduced ejection fraction, people with hypertension, adults with edema from cirrhosis of the liver or the nephrotic syndrome, and people with primary hyperaldosteronism. The passages read do not state an age range for each use.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated for each use in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label says the heart failure use is usually together with other heart failure therapies; that is not an atlas recommendation. Contraindications, warnings (including raised potassium), interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Supports: openFDA drug label record for Aldactone (spironolactone tablets), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class (Regulator, edition The openFDA drug label record for set id 0fed2822-3a03-4b64-9857-c682fcd462bc (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA012151), returned on 2026-11-18. The label text is dated 2025-11-28 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%220fed2822-3a03-4b64-9857-c682fcd462bc%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-18T17:27:10Z. Source state: Current. Version fingerprint: 7a66be80d86367d4142306a143a4c600b7a1fd0b1e32977782824e8cd08cdc91.
     How it applies: Label passage quoted in the research quote table (LB-04).
  2. Supports: openFDA drug label record for Aldactone (spironolactone tablets), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class (Regulator, edition The openFDA drug label record for set id 0fed2822-3a03-4b64-9857-c682fcd462bc (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA012151), returned on 2026-11-18. The label text is dated 2025-11-28 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%220fed2822-3a03-4b64-9857-c682fcd462bc%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.1 Heart Failure. Retrieved 2026-11-18T17:27:10Z. Source state: Current. Version fingerprint: 7a66be80d86367d4142306a143a4c600b7a1fd0b1e32977782824e8cd08cdc91.
     How it applies: Label passage quoted in the research quote table (LB-05, LB-10).
  3. Supports: openFDA drug label record for Aldactone (spironolactone tablets), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class (Regulator, edition The openFDA drug label record for set id 0fed2822-3a03-4b64-9857-c682fcd462bc (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA012151), returned on 2026-11-18. The label text is dated 2025-11-28 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%220fed2822-3a03-4b64-9857-c682fcd462bc%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.2 Hypertension. Retrieved 2026-11-18T17:27:10Z. Source state: Current. Version fingerprint: 7a66be80d86367d4142306a143a4c600b7a1fd0b1e32977782824e8cd08cdc91.
     How it applies: Label passage quoted in the research quote table (LB-06).
  4. Supports: openFDA drug label record for Aldactone (spironolactone tablets), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class (Regulator, edition The openFDA drug label record for set id 0fed2822-3a03-4b64-9857-c682fcd462bc (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA012151), returned on 2026-11-18. The label text is dated 2025-11-28 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%220fed2822-3a03-4b64-9857-c682fcd462bc%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.3 Edema Associated with Hepatic Cirrhosis or Nephrotic Syndrome. Retrieved 2026-11-18T17:27:10Z. Source state: Current. Version fingerprint: 7a66be80d86367d4142306a143a4c600b7a1fd0b1e32977782824e8cd08cdc91.
     How it applies: Label passage quoted in the research quote table (LB-07, LB-11).
  5. Supports: openFDA drug label record for Aldactone (spironolactone tablets), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class (Regulator, edition The openFDA drug label record for set id 0fed2822-3a03-4b64-9857-c682fcd462bc (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA012151), returned on 2026-11-18. The label text is dated 2025-11-28 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%220fed2822-3a03-4b64-9857-c682fcd462bc%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.4 Primary Hyperaldosteronism. Retrieved 2026-11-18T17:27:10Z. Source state: Current. Version fingerprint: 7a66be80d86367d4142306a143a4c600b7a1fd0b1e32977782824e8cd08cdc91.
     How it applies: Label passage quoted in the research quote table (LB-08, LB-12).
  6. Background: openFDA drug label record for Aldactone (spironolactone tablets), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class (Regulator, edition The openFDA drug label record for set id 0fed2822-3a03-4b64-9857-c682fcd462bc (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA012151), returned on 2026-11-18. The label text is dated 2025-11-28 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%220fed2822-3a03-4b64-9857-c682fcd462bc%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T17:27:10Z. Source state: Current. Version fingerprint: 7a66be80d86367d4142306a143a4c600b7a1fd0b1e32977782824e8cd08cdc91.
     How it applies: Effective date of the label text read, 20251128.

## Connected pages

- Spironolactone is an aldosterone antagonist (FDA established pharmacologic class in RxClass): Mineralocorticoid receptor antagonists (drug class) (`cardio:mineralocorticoid-receptor-antagonists`)
- FDA label lists NYHA class III to IV heart failure with reduced ejection fraction as an indication: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`) [a claim, not a settled fact; see claim `cardio:claim-fda-spironolactone-label-indications` and its context]
- FDA label lists add-on treatment of hypertension as an indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-spironolactone-label-indications` and its context]
- FDA label lists primary hyperaldosteronism as an indication: Primary aldosteronism (`cardio:primary-aldosteronism`) [a claim, not a settled fact; see claim `cardio:claim-fda-spironolactone-label-indications` and its context]
- The mineralocorticoid receptor antagonist class is one of the four classes of the heart failure regimen: Four-class medicine regimen in heart failure (guideline-directed medical therapy) (`cardio:hfref-four-medicine-regimen`)
- Files under this front: Medicines (`cardio:front-medicines`)

## Provenance

Content hash: 623116861745a51c1146b1091d7a921d11dfd2f1ae34d642fa946fff70c173a3
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
